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Abstract
Expression of CD44, a transmembrane hyaluronan-binding glycoprotein, is variably considered to have prognostic
significance for different cancers, including oral squamous cell carcinoma. Although unclear at present, tissue-specific
expression of particular isoforms of CD44 might underlie the different outcomes in currently available studies. We mined
public transcriptomics databases for gene expression data on CD44, and analyzed normal, immortalized and tumour-
derived human cell lines for splice variants of CD44 at both the transcript and protein levels. Bioinformatics readouts, from a
total of more than 15,000 analyses, implied an increased CD44 expression in head and neck cancer, including increased
expression levels relative to many normal and tumor tissue types. Also, meta-analysis of over 260 cell lines and over 4,000
tissue specimens of diverse origins indicated lower CD44 expression levels in cell lines compared to tissue. With minor
exceptions, reverse transcribed polymerase chain reaction identified expression of the four main isoforms of CD44 in normal
oral keratinocytes, transformed lines termed DT and HaCaT, and a series of paired primary and metastasis-derived cell lines
from oral or pharyngeal carcinomas termed HN4/HN12, HN22/HN8 and HN30/HN31. Immunocytochemistry, Western
blotting and flow cytometric assessments all confirmed the isoform expression pattern at the protein level. Overall,
bioinformatic processing of large numbers of global gene expression analyses demonstrated elevated CD44 expression in
head and neck cancer relative to other cancer types, and that the application of standard cell culture protocols might
decrease CD44 expression. Additionally, the results show that the many variant CD44 exons are not fundamentally
deregulated in a diverse range of cultured normal and transformed keratinocyte lines.
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Introduction
CD44 plays an important role in many cell processes including
growth, survival, differentiation, and motility [1], by binding ligands
such as hyaluronan, osteopontin, collagens, growth factors, and
matrix metalloproteinases. CD44 is a large, highly conserved, and
complex gene containing 19 exons located on human chromosome
11 [2] and mouse chromosome 2 [3]. The predominant CD44
transcript (exons 1–5 and 16–20) produces the standard or
haemopoietic form of CD44 (CD44s or CD44h) [4]. The remaining
exons (6–15) are variably spliced and referred to as variant exons 1–
10 (v1-10). In humans, exon 6 (v1) contains a stop codon and
therefore, the first transcribed variant exon of human CD44 is exon
7 (v2) [5]. The differential utilisation of these variant exons,
commonly in tandem blocks rather than independently, generates
multiple CD44 variants and these subsequently undergo post-
translational modification. The 39 expression arrays that form the
majority of the current publicly available gene expression databases
cannot discriminate between alternatively spliced variants of CD44
because the transcripts have identical 39 ends, however, many
studies have been published using CD44v specific primers and
antibodies for the detection of CD44 spliced variants.
CD44 is constitutively expressed by almost all cell types [6,7],
but CD44 variant exons (CD44v) have a more restricted
distribution and, possibly, function. CD44 alternative splicing is
related to neoplasia and metastasis in many cancers [8]. However,
evidence for the role of CD44v in oral squamous cell carcinoma
(OSCC) is conflicting. Like keratinocytes of the epidermis, mucosal
keratinocytes express all variant exons constitutively [9,10,11,12],
consistent with a role for CD44 in structural integrity. Immuno-
histochemical techniques have suggested that a loss of expression
of variant exons in OSCC correlates with higher histological grade
and metastasis. Although studies differ, the most frequently
implicated variant exons in oral and head and neck squamous
cell carcinoma (HNSCC) are v4, 7, 8, and 9 [11,13,14,15].
We have previously shown overexpression of CD44v transcripts
in OSCC primary tumour samples compared with normal oral
mucosa [16]. The splicing patterns of tumour samples and of
OSCC cell lines were very similar to normal oral epithelium and
normal oral keratinocytes [12,16]. However, the transcripts were
only variably translated to protein [12]. The assembly of public
gene expression data into databases, such as the In Silico
Transcriptomics database (IST) and the Human Gene Expression
Map (HGEM), provide means to assess the expression of genes
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ally, CD44 gene expression levels can be compared among various
cancer types, other diseases, and cell lines.
In the present study, we mined transcriptomics databases for
CD44 expression with particular reference to oral and pharyngeal
squamous cell carcinoma (OPSCC). Additionally, we assessed
CD44v transcription and expression in a range of normal,
immortalized and tumour-derived epithelial cell lines, including
previously uncharacterized lines from three paired primary
tumour and lymph node OPSCC metastases.
Materials and Methods
Ethics Statement
The isolation and culture of the normal oral keratinocytes used
in this study was approved by the ethical committee at the
Karolinska Institutet, Reference number 01-092. Each patient
provided informed written consent.
Assessment of CD44 expression in the In Silico
Transcriptomics (IST) database and the Human Gene
Expression Map (HGEM) database
CD44 expression was assessed from bioinformatics-based mining
of the IST database (compiled from 9783 Affymetrix gene
expression analyses in 43 normal tissues, 68 cancer types and 64
other diseases) and the HGEM database (compiled from 5372
gene expression analyses from 369 different cell and tissue types,
disease states and cell lines). Both databases are publically
available at http://www.genesapiens.org and http://www.ebi.ac.
uk/gxa/experiment/E-MTAB-62, respectively [17,18].
Applying the IST database, tissue and disease-wide expression
profiles were generated for CD44 with samples represented on the
x-axis (normal, cancer, and other diseases) and relative gene
expression values on the y-axis. Applying the HGEM database,
statistical analyses of six probes on the Affymetrix HG-U133A
array that target the CD44 gene were derived across 96 ‘biological
groups’ (cell or tissue types with more than 10 biological replicates
among the 369 states) and 4 ‘meta groups’ to assess the expression
differences relative to normal, neoplastic, disease and cell line
phenotypes.
Maintenance and culture of primary and secondary cell
lines
Cell culture reagents were from Sigma-Aldrich, Gillingham,
Dorset, UK unless otherwise indicated. Normal oral keratinocytes
(NOK) were obtained from healthy, non-smoking donors
undergoing maxillofacial surgery (approved by the ethical
committee at the Karolinska Institutet) and cultured as previously
described [19]. Briefly, primary cell cultures were derived from
tissue digestion with trypsin overnight at 4uC, and the mixture was
resuspended in a serum-free epithelial medium with high levels of
amino acids (termed EMHA) or Keratinocyte-SFM media (Gibco,
Invitrogen Corporation, Paisley, UK) and seeded onto dishes that
had been pre-coated with fibronectin/collagen. These media were
used interchangeably without detectable differences in growth or
outcome of the experiments. Cultures were transferred onto
regular tissue culture plastic at approximately 75% confluence,
and cells in passage 2 were used in the experiments.
HPV immortalised epidermal keratinocytes (DT) were kindly
provided by Prof. I. M Leigh. Three cell line pairs HN4/HN12,
HN22/HN8, HN30/HN31, kindly provided by Dr. A Yeudall,
were established from primary tumour and lymph node metastases
from three individuals with squamous cell carcinomas of the
tongue, epiglottis, and pharynx, respectively [20]. DT cells, the
three cell line pairs, and the spontaneously immortalised epidermal
human skin cell line HaCaT [21] were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% foetal
calf serum (FCS), 2 mM glutamine, and 100 mg/ml penicillin/
streptomycin. Two cell lines, OSC-19 and -20, isolated from
squamous cell carcinomas of the tongue that metastasised to a
cervical lymph node [22], and were metastatic in nude mice, were
maintained in a 3:1 ratio of DMEM:F-12 Ham’s medium (Sigma)
supplemented with 10% FCS, 10 ng/ml epidermal growth factor
(EGF), 0.5 mg/ml hydrocortisone, 5 mg/ml transferrin, 5 mg/ml
insulin, 1.8610
24 M adenine, 1610
210 M cholera toxin, 100
units/ml penicillin, and 100 mg/ml streptomycin. Namalwa, an
Epstein-Barr virus immortalised Burkitt’s lymphoma line [23], was
grown in RPMI-1640 medium supplemented with 10% FCS and
used as a negative control.
Reverse transcription-polymerase chain reaction (RT-PCR)
RNA was extracted from cells using RNeasy spin columns
(Qiagen, Crawley, West Sussex, UK) as previously described [12].
Synthesis of first strand cDNA from 2.5 mg of total RNA was
carried out using 12.5 ng of Oligo (dT) primers (Invitrogen Ltd,
Paisley, UK), and denatured at 70uC for 10 minutes. The samples
were then placed on ice for 5 minutes, before adding 16 first
strand buffer, 10 mM DTT (Dithiothreitol; Invitrogen), and
500 mM of each dNTP. After a 2 minute annealing incubation
at 42uC, 10 units of Superscript II reverse transcriptase
(Invitrogen) were added and further incubated for 50 minutes at
42uC. A final 15 minute incubation at 70uC terminated the
reaction, and the resultant cDNA was stored at 220uC.
Hot start PCR was performed on cDNA primers for total CD44
(CD44 P1 and P2 primers), individual variant exons (CD44 P1 and
exon-specific reverse primers for v1 to v10) [24], and b actin [25]
(see Table 1 for primer sequences). 5 ml of cDNA, 20 mM Tris-
HCl (pH 8.4), 50 mM KCl, 16Q solution (Qiagen), 200 mMo f
each dNTP, and 20 mM of each 59 and 39 primer was denatured
for 5 minutes at 95uC, followed by a 10 minute 72uC elongation
phase during which 0.25 units of Taq DNA polymerase (Qiagen)
were added. Amplification of DNA was performed in a Perkin-
Table 1. RT-PCR Primer Sequences.
Primer Primer Length (bases) Sequence (59 to 39 direction)
CD44 P1 F 21 TCCCAGTATGACACATATTGC
CD44 P2 R 20 CACCTTCTTCGACTGTTGAC
CD44 v1 R 20 CTGTGAATTACCAAACCAGG
CD44 v2 R 20 TGCTGTAGCACTAGTGCTCA
CD44 v3 R 20 TCATTTGGCTCCCAGCCTGC
CD44 v4 R 21 TTGTCTGAAGTAGCACTTCCG
CD44 v5 R 21 GTTCCAGTTTCCTTCATAAGC
CD44 v6 R 20 CCCACATGCCATCTGTTGCC
CD44 v7 R 21 AATCAGTCCAGGAACTGTCCT
CD44 v8 R 21 GTGTTTGGATTTGCAGTAGGC
CD44 v9 R 21 GTCTTTATCTTCTTCCAAGCC
b actin F 20 CGTACCACTGGCATCGTGAT
b actin R 21 GTGTTGGCGTACAGGTCTTTG
Key: F=Forward Primer, R=Reverse Primer.
For CD44v,t h eCD44 P1 F primer was combined with the exon-specific reserve
primer.
doi:10.1371/journal.pone.0028776.t001
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denaturation for 1 minute at 95uC, annealing for 1 minute at
57uC, and elongation for 2 minutes at 72uC. Reaction products
were resolved by electrophoresis on a 1.5% agarose gel. To
confirm specificity of amplification, PCR products were purified
(QIAquick, Qiagen), sequenced (Perkin Elmer ABI 377), and their
identity confirmed using BLAST software from NCBI (Zhang and
Madden, 1997).
Immunocytochemistry (ICC)
Cells in log growth phase were detached by trypsinisation and
resuspended in medium with 10% FCS at 2610
4 cells/ml. 20 ml
aliquots of cell suspension were applied to APES treated
polytetrafluoroethylene-coated microscope slides and grown for 2
days at 37uCi n5 %C O 2.
Slides were blocked in 3% hydrogen peroxide in 50% methanol
for 30 minutes to stop endogenous peroxide activity and then in
20% normal rabbit serum (DAKO Ltd, Ely, Cambridgeshire, UK)
for 10 minutes to block non-specific binding. They were then
incubated for 60 minutes with primary antibody (see Table 2),
followed by 30 minutes each in secondary biotinylated rabbit anti-
mouse antibody (1:300, DAKO) and streptavidin-biotin horserad-
ish peroxidase (1:50, DAKO). Binding was visualised with 3,39
diaminobenzidine (DAB; DAKO Ltd, UK) and slides were
counterstained with haematoxylin (VWR International Ltd,
Lutterworth, Leicestershire, UK). Isotype-matched irrelevant
antibodies were used as negative controls. All of the antibodies
were reported to be suitable for ICC by the manufacturers, and
the optimum titre was determined separately.
Western blotting
Cells were lysed for 10 minutes on ice with NP40 buffer and the
postnuclear supernatant was stored at 270uC. Protein concentra-
tions were determined by Coomassie blue dye-binding (Bio-rad
Laboratories, Hemel Hempstead, Hertforshire, UK). Then 25 mg
of protein was boiled for 5 minutes with gel-loading buffer and
resolved in an 8% polyacrylamide-SDS gel and transferred to
immobilon-P membrane (Millipore UK Ltd, Croxley Green,
Watford, UK) using a semi-dry method. Non-specific binding sites
were blocked with 5% dried skimmed milk or BSA in PBS
containing 1% Tween 20. Blots were probed with primary
antibodies against total CD44, individual variant exons, or b actin
(Table 2), and visualised using horseradish peroxidase-conjugated
(HRP) secondary antibody (1:5000–1:10,000 sheep anti-mouse,
GE Healthcare, Amersham, Buckinghamshire, UK) for CD44, or
(1:1000 goat anti-mouse, DAKO Ltd, UK) for b actin and
enhanced chemiluminescence (ECL, Amersham). All the primary
antibody concentrations were titrated in the range 2–10 mgm l
21
using test blots, to determine the optimum concentrations.
Flow cytometric analysis
Approximately 1610
66 cells were washed and resuspended in
100 ml PBS containing 2.5% FCS and incubated for 1 hour at 4uC
with the primary antibody (Table 2) at concentrations determined
by control titration assays. Cells were then incubated with FITC-
conjugated goat Fab9 fragments directed against mouse IgG
(1:5,000, Cappel Laboratories, Malvern, PA, USA) for 30 minutes
at 4uC. After washing, the cells were fixed using 2% paraformal-
dehyde in PBS, and 10,000 events were analysed by flow
cytometry on a FACScan (Becton Dickinson UK Ltd, Littlemore,
Oxford, UK). Background/non-specific staining was subtracted
using controls stained with irrelevant isotype-matched antibody at
the same concentration.
Results
CD44 expression in normal and disease tissues
The expression of CD44 was assessed initially at transcript level
by mining the IST database that includes tissue samples from
normal non-neoplastic tissues, malignant neoplasms and other
diseases (Figure 1). Relative plotting displayed elevated expression
levels of CD44 in head and neck cancer as well as in acute myeloid
leukemia (AML) and lung carcinoid tumors relative to 65 other
cancer types (see box in the ‘‘Cancer’’ compartment). The relative
expression level among specimens from these cancer types differed
within a 10-fold range. Above average expression was also noted
for five types of normal, non-neoplastic tissue, although notably,
not for normal reference samples to HNSCC (see box in ‘Healthy’
compartment). The ‘Other diseases’ compartment did not indicate
elevated CD44 expression (Figure 1).
Next, we assessed CD44 expression in the HGEM (Table 3). Six
probes targeting CD44 displayed significantly increased expression
in the oral squamous cell carcinoma group relative to 95 other
biological groups. Due to the inclusion of 369 cell line samples in
the HGEM, we next compared this entity versus normal,
neoplastic and diseased tissue specimens. The normal and
neoplasm groups showed increased expression of CD44 for
between five and six probes, respectively, whereas decreased
expression of CD44 was found for five out of six probes in the
disease and cell line groups (Table 3). The cell line group included
only one line from the head and neck region, i.e., the tongue
squamous cell carcinoma line Cal27, which showed elevated
expression for all probes relative the other cell lines (data not
shown).
Transcription of CD44 isoforms
Amplification of housekeeping gene b actin generated a 411 bp
band from all cell lines confirming the integrity of cDNA
(Figure 2A). No bands were seen in the negative control.
Using the standard total CD44 PCR primers, P1 and P2, it can
be seen that all cell lines produced a transcript at 549 bp,
indicating transcription of CD44s (Figure 2B). Additional bands,
using these primers, were also seen at approximately 1 kb, 1.3 kb,
1.6 kb, and 1.7 kb, consistent with transcription of CD44
containing variant exons v8-10, v6-10, v3-10, and v2-10,
Table 2. Primary Antibodies.
Final Concentration
(mg/ml)
Antibody Clone/Code Source Isotype ICC WB FC
b actin 1I g G -2 -
CD44S 2C5 3 IgG2A 1 2 16.7
Exon v3 3G5 4 IgG2b 2 2 16.7
Exon v4 VFF11 4 IgG1 1 2 16.7
Exon v5 VFF8 4 IgG1 5 2 16.7
Exon v6 2F10 4 IgG1 1 2 16.7
Exon v7 VFF9 4 IgG1 5 2 16.7
Exon v7/8 VFF17 4 IgG2b 2 0.5 16.7
Exon v9 441V 5 IgG1 2 2 16.7
Exon v10 VFF14 4 IgG1 20 2 90
1 – Santa Cruz, USA, 2 – Dako Ltd, UK, 3 – R&D Systems, UK, 4 – Serotec, UK, 5 –
AmsBiotech (Europe) Ltd.
doi:10.1371/journal.pone.0028776.t002
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(lanes 2 and 6, respectively) was not compatible with any
recognised combination of variant exons. Few, if any, differences
were detected between each of the two pairs of cell lines;
HN4:HN12, HN22:HN8, and HN30:HN31 (lanes 3:4, 6:5, and
7:8, respectively) apart from the additional band at 800 bp seen in
HN22 (lane 6) but not in its metastasis-derived partner HN8 (lane
5).
Transcription of individual variant exons
Exon specific PCR amplifies CD44 from the 59 end of CD44s
(constituitive exons 3 to 5) and all of the variant exons spliced to it.
For example, the variant exon v4 reverse primer, together with the
standard forward primer P1, will amplify exons 3–5 and v2-4 (v1
not transcribed in humans). When the products from each variant
exon primer were resolved in sequence on a gel, a stepwise
sequence of bands of progressively larger size was observed
(Figures 3A and B) reflecting sequential exon transcription.
Additional linear diagonal patterns of bands of smaller size were
also seen, consistent with shorter transcripts containing fewer
variant exons.
Overall, there was a tendency to start variant transcription at
exon v2, v3, v4, v6, or v8. Variant exon 1 was not transcribed at
all consistent with other known sequences (Table 4, Figure 3A–J).
It can be seen that all cell lines produced four similar transcripts;
v2-10, v3-10, v6-10, and v8-10, except HN22, which lacked v3-10.
The next most common transcript was v4-7 in HN8, HN12,
HN30, HN31, and OSC-19 cells, then v7-10 in DT, HN22,
HN31, and OSC-20 cells, followed by v4-6 in NOK, HN22, and
OSC-20 cells. Some transcripts were identified in only a minority
of cells, such as a long transcript v4-10 in DT cells, and a short
minor transcript v9-10 in OSC-20 cells.
Within each primary-derived and metastasis-derived pair there
were no large differences in splicing pattern. Apart from HN22, all
produced the four transcripts described above and only one or two
short transcripts. A few small differences in transcription patterns
were detected within each matched pair. In HN4 the v2-10
transcript was a major band but in HN12 it was minor; HN12 had
an additional transcript v4-7; minor transcripts v7-10 and v4-6
were not observed in HN8 and the major transcript v3-10 and
minor transcript v4-7 were not found in HN22. One minor
transcript found in HN31 (v7-10) was not present in HN30 and
Figure 1. Expression profiles of CD44 from the In Silico Transcriptomics database. Each sample is represented by a dot and colour coded
as in the ‘anatomical systems box’. The samples are divided into three sections; healthy, cancer and other diseases. Samples with higher average
expression levels are indicated in colour in the figure, and the corresponding tissues are displayed in the top left of the respective sections, i.e., higher
than average expression for CD44 was observed in tumour samples from acute myeloid leukaemia, head and neck cancer (indicated by arrow) and
lung carcinoid tumour.
doi:10.1371/journal.pone.0028776.g001
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transcripts in HN31.
CD44 expression assessed by immunocytochemistry
(ICC)
In all experiments, isotype-matched negative controls and no-
antibody controls showed complete absence of staining. The
positive control NOK cells stained for total CD44 and all the
variant exons. The staining intensity was scored quantitatively
from 0 (absent) to 3. The proportion of cells showing membrane
staining was assessed as homogenous (90–100% of cells stained),
heterogenous (50–90% of cells stained), occasional (10–40% of
cells stained), or sparse (,10% of cells stained). The results from
ICC of CD44s and variant exons are summarised in Table 5 and
representative images are shown in Figure 4A.
All cell lines stained intensely for total CD44s protein with
.50% of cells stained, except for HN12 where only occasional
(,10%) cells were stained. All cell lines also stained (.50% of
cells stained) for v3, v5, v6, and v9. The next most common
transcript was v10, for which only OSC-20 did not stain, and
other cell lines had occasional cells staining. Detailed analysis is
shown in Table 5.
There were minimal differences, limited to percentages of cells
stained, between the protein expression patterns of the paired
OPSCC cell lines based on immunocytochemistry. The only clear
difference was that for v7, for which HN4 did not stain, while its
metastasis-derived partner HN12 stained sparsely.
CD44 expression by western blotting
Positive control DT and HaCaT cell lines showed positive
bands for all blots probed with CD44 antibodies. Negative control
Namalwa cell line generated only bands below 60 kDa and
100 kDa respectively, for v4 and v9 identified as false positives on
basis of size. Blots probed with antibody to b actin produced the
expected 42 kDa band. The results for the cell lines probed with
total CD44 and variant CD44 antibodies are summarised in
Table 5 and representative blots are shown in Figure 4B.
All cell lines with the exception of HN8 expressed total CD44
and the majority showed multiple isoforms. The greatest number
of bands was expressed by the HN12 cells, which showed bands at
approximately 145 kDa, 180 kDa, and faint bands at 90 kDa,
130 kDa, and 200 kDa. CD44 v3 was expressed in bands at
90 kDa, 120 kDa, 130 kDa, and a smear at 185–200 kDa, except
in OSC-20 and HN22 cell which did not express v3 at all.
Significantly there was some differential expression between cells
of the 120 and 130 kDa bands; HN4, and HN8 both expressed the
120 kDa band, whereas HN12, HN30, and HN31 all expressed
the 130 kDa band.
Table 3. Meta-analyses of CD44 Expression in the Human Gene Expression Map
a.
CD44 (probe id) Oral squamous cell carcinoma
b Normal
c Neoplasm
c Disease
c Cell line
c
204489_s_at Up Up Up Down Down
(1.03*10
29) (2.86*10
24) (3.57*10
28) (0.018) (1.48*10
28)
204490_s_at Up Up Up Down Down
(,1*10
210) (0.001) (3.26*10
26) (0.027) (3.1*10
26)
209835_x_at Up Up Up Down Down
(,1*10
210) (0.004) (9.57*10
27) (0.033) (3.38*10
26)
210916_s_at Up Non d-e Up Down Non d-e
(0.002) (0.11) (0.003) (1.15610
25) (0.369)
212014_x_at Up Up Up Down Down
(,1*10
210) (0.03) (3.67*10
27) (0.01) (4.43*10
24)
212063_at Up Up Up Up Down
(,1*10
210)( ,1*10
210)( ,1*10
210) (1.55610
24)( ,1*10
210)
aCD44 expression assessment in the human gene expression map. The database contains 5372 samples hybridized to the Affymetrix HG-U133A array platformf o r
comparison of the expression levels relative to various biological variables e.g., 96-groups or 4-meta groups. Direction of change (Up, Down or Not differently
expressed (non d-e)) and p-values (bracketed) is indicated for the respective ‘‘groups’’ for probes targeting CD44. A p,0.05 was considered significant. For details, see
Materials and Methods.
bAssessment of the biological variable ‘‘96-groups’’ that includes the group ‘‘oral squamous cell carcinoma’’ relative to CD44 expression. Each of the 96-groups contains
at least 10 biological replicate samples. The OSCC group contains 23 samples from one study [65].
cAssessment of the biological variable ‘‘4-meta groups’’. The normal group contains 1033 samples, neoplasm 2315 samples, disease 765 samples and cell line 1259
samples.
doi:10.1371/journal.pone.0028776.t003
Figure 2. Amplification of b actin and CD44. RT-PCR was
performed, and resolved on a 1.5% agarose gel with a 100 bp ladder.
Lanes 1–10 contain NOK, DT, HN4, HN12, HN8, HN22, HN30, HN31, OSC-
19, OSC-20. (A), bands at 411 bp are b actin product band. (B), With P1
and P2 primers, bands at 549 bp indicate presence of CD44s RNA in all
samples. In addition, NOK and all the other lines produce isoform bands
consistent with splicing of variant exons (bands at 1 kb, 1.3 kb, and
1.7 kb). M=100 bp marker, and Lane 11 water control.
doi:10.1371/journal.pone.0028776.g002
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but some cells also expressed further bands at 160 and 180–
90 kDa (HN4, HN12, and HN8). OSC-20 did not express v6, but
the other cell lines all had a smear at 180–190 kDa. Some cell lines
also had an additional band at 130 kDa. All cell lines expressed v7
with bands at 120 or 130 kDa, some minor bands were also
present at 160 and 100 kDa. Two main bands were also found for
v9 at 120–130 kDa, and some cells also expressed another band at
180–190 kDa. No correlation was found for any of these
expression patterns between the cell lines of each pair. All
remaining variants (v5, v7/8, v10) were expressed by all cell lines
but there were no differences in their expression between the cell
lines.
CD44 expression by flow cytometry
The results for flow cytometry are summarised in Table 5 and
representative plots are shown in Figure 4C. All cell lines
expressed total CD44 with a greater than 50% increase in mean
channel fluorescence (MCF). The most frequently undetected
variant exon was v7, followed by v10 and v4. As with other
techniques OSC-20 was found to express the fewest variant exons.
The main differences between the paired samples were that HN4
Figure 3. Amplification of CD44 variant exons. RT-PCR was performed using exon specific primers (lanes 1–10 were exons v1 to v10,
respectively), and resolved on a 1.5% agarose gel with a 100 bp ladder. NOK cells (A), DT cells (B), OSC-19 (C), and OSC-20 (D) and three matched
primary and metastasis derived OPSCC cell line pairs; HN4 (E) and HN12 (F), HN22 (G) and HN8 (H), and HN30 (I) and HN31 (J) were assessed.
doi:10.1371/journal.pone.0028776.g003
Table 4. Summary of CD44 variant transcripts.
Cells CD44 Transcripts
v2-10 v3-10 v4-10 v6-10 v7-10 v8-10 v9-10 v4-7 v4-6
NOK NN
## #
DT NN
####
HN4 NN
##
HN12 # N
###
HN22 NN
# N
#
HN8 NN N N
#
HN30 NN
###
HN31 NN N
# N
#
OSC-19 NN N N
#
OSC-20 # NN
# N
##
N Major band # Minor band
doi:10.1371/journal.pone.0028776.t004
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lacked v10. Expression of v4 was infrequent in HN30 (.15 ,50%
increased MCF) but in HN31 it was highly expressed (.50%
increased MCF). HN22 could not be analysed by flow cytometry.
Discussion
Genome-wide transcriptomic profiles have revealed that head
and neck cancer is a heterogeneous disease, impeding accurate
prognostication and identification of genes contributing to
carcinogenesis. Our previous work indicated higher CD44
expression in oral squamous cell carcinoma tissue compared to
normal tissue counterparts [16]. To understand whether this
increased expression is related to all cancers or just oral and head
and neck cancers specifically, we mined the two currently existing
major public transcriptomics databases for CD44 expression.
The assessment of overall more than 15000 gene expression
analyses showed that head and neck cancers had elevated
expression compared to the majority of other solid cancers, and
also, that CD44 expression levels might decrease from application
of culturing protocols (Figure 1 and Table 3). Large variations
were noted among all samples and categories in both databases,
possibly related to tumour heterogeneity, variable differentiation
states, clonal differences or presence of putative stem cell
populations. Although our previous limited sample data analysis
suggested similar CD44 expression levels in tissues and cell lines
for the head and neck region [16], the absence of stromal
influences or general culture-dependent enrichments for prolifer-
Table 5. Summary of total CD44 and variant exons detected by immunostaining, western blotting, and flow cytometry.
Cells Total CD44 CD44 Variant Exons
v3 v4 v5 v6 v7 V7/8 v9 v10
Immunostaining
NOK 2–3 3 1–2
S 32 – 3
H 2
S 32
H 3
H
DT 1–3
H 2–3 0 2–3 1–2
H 0 2 1–2 1–2
OC
HN4 2–3 2–3
H 1–2
OC 1–2
H 2–3
H 02 – 3
H 2–3
H 2–3
OC
HN12 2–3
S 2–3
OC 2–3
OC/S 2–3
H 2–3
H 2–3
S 2–3
H 2–3
S 2
OC
HN22 - - - - - --- -
HN8 2–3
H 30 1 – 2
H 2–3 0 0 2–3 2
OC
HN30 2–3
H 2–3 2
H 2–3 2–3 0 1–3
H 2–3 2
HN31 2–3 1–3 1–2
S 2–3
H 20 2
OC 2–3
H 2
H
OSC-19 2–3 1–3 1–2
H 33 2 – 3 2
H 2–3 3
H
OSC-20 2–3 1–2
OC 02
H 2–3
OC 0 0 1–2
H 0
Western Blotting
DT ACD CD C CD CD BC DE BC DE
HN4 ACD BD CD CD D B DE BC DE
HN12 ACD CD CD CD CD BC DE BC DE
HN22 ACD 0 C CD D BC DE BC DE
HN8 0 BC CD CD D BC DE BC DE
HN30 CD CD C CD CD C DE BCD DE
HN31 CD CD C CD CD BC DE BCD DE
OSC-19 ACD CD C CD CD BC DE BCD DE
OSC-20 A0 C C D 0 B D E B C D D E
Flow Cytometry
DT ++ ++ 2 ++ ++ 2 ++ ++ +
HN4 ++ ++ ++ ++ ++ 2 ++ ++ ++
HN12 ++ ++ ++ ++ ++ ++ ++ ++ 2
HN22 nt nt nt nt nt nt nt nt nt
HN8 ++ ++ ++ ++ ++ + ++ ++ ++
HN30 ++ ++ + ++ ++ 2 ++ + 2
HN31 ++ ++ ++ ++ ++ 2 ++ + 2
OSC-19 ++ ++ ++ ++ ++ ++ ++ ++ +
OSC-20 ++ + 2 ++ +2 ++ ++ 2
Immunostaining. 0=no staining; 1 to 3=increasing intensity of membrane staining.
S=sparse (,10% of cells stained);
OC=occasional (10 to 40% of cells stained);
H=heterogeneous (50 to 90% of cells stained); and finally, homogenous staining (90–100% of cells stained) has no superscripted symbol.
NOTE: HN22 cell line failed to grow for analysis.
Western Blotting. Band sizes: A=90 kDa, B=120–125 kDa, C=130–170 kDa, D=180–200 kDa, E=230–250 kDa, 0=no expression.
Flow cytometry. ++=50% increase in MCF, +=.15 ,50% increase in MCF, 2=no increase in MCF, nt=not tested.
doi:10.1371/journal.pone.0028776.t005
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specific, cell populations might underlie the generally noted lower
expression level of CD44 from bioinformatics-based sorting of
large numbers of cell lines.
Current bioinformatics-based expression data cannot distin-
guish isoforms of CD44. On this basis, we explored also the
possibility of alternative splicing of CD44 in several cell lines for
the head and neck region, including normal, immortalized and
tumor-derived lines, the latter including previously uncharacter-
ized derivatives from matched pairs of normal and metastatic
tissue. We hypothesised that given the role of CD44v in other
cancers, that the individual isoforms could also play an integral
role in oral cancers.
All the experimental work was performed on cell lines, and so it
cannot be interpreted in relation to any possible CD44 positive
cancer stem cell phenotype. Expression of CD44 marks a putative
squamous cell carcinoma stem cell population, but only a minority
of expressing cells with a basal phenotype have stem cell properties
[26]. It appears that hyaluronan binding triggers pleuripotential
stem cell regulating genes [27] so that CD44 variants would differ
in this activity. The role of CD44 and splice variants as stem cell
markers in squamous carcinomas remains to be fully confirmed
and there are several alternative hypotheses to link such a
constitutively and abundantly expressed molecule with stem cell-
like properties [28].
Transcription of total CD44 and individual variant exons
Few studies have used exon-specific primers to study all variant
exon-containing CD44 isoforms in HNSCC, most have used P1/
P2 or equivalent primers [9,29], to detect total CD44 or CD44s.
Two studies have used exon-specific primers for CD44 v3, finding
that v3 transcripts are higher in tumour tissues than normal [29]
and suggested that it is linked with growth and migration [30] in
HNSCC.
All of the OSPCC cell lines in this study transcribed CD44s and
the four typical keratinocyte isoforms to varying degrees, except
HN22, which failed to transcribe v3-v10. In addition, a variety of
other variant exon-containing transcripts were identified. Howev-
er, no major differences were identified between NOK and DT
cells, and between each of the paired primary and metastasis
derived lines (HN4:HN12, HN22:HN8, and HN30:HN31), and
the lines that were metastatic in nude mice (OSC-19, and OSC-
Figure 4. Detection of total CD44 and variant CD44 protein. Representative figures of immunostaining with all cells stained positive in this
field (A), western blotting (B), and flow cytometry (C). (A) Immunostaining of HN12 cells for total CD44, an isotype matched control, v3, v4, v5, and v6.
(B) Western blotting lanes 1–12 contain MW marker, HaCaT, HN4, HN12, HN8, HN22, HN30, HN31, OSC-19, OSC-20, DT, and Namalwa cells, repectively.
(C) flow cytometry results for HN4 and HN12 cells detecting v7 and v10.
doi:10.1371/journal.pone.0028776.g004
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of these OPSCC lines are very similar to normal keratinocytes,
and appear not to be related to their stable metastatic phenotype.
Transcription patterns in OPSCC lines are better preserved
than those reported in breast, bladder, colon, and lung
carcinomas. These carcinomas have been shown to transcribe a
wider range of splice variants [31], more transcripts that exceed
1.5 kb [32], more transcripts with variant exons [33], and to
express preferentially one isoform over another [34]. It is
intriguing that splicing patterns in OPSCC appear essentially
normal despite the fact that the genome of OPSCC shows much
more damage than malignant neoplasms at sites not exposed to
tobacco and alcohol. It is possible that normal CD44 expression
has a survival advantage to malignant cells and mechanisms might
include improved cohesion and variant exon 6 and 7 ligation to
osteopontin, which signals for cell survival via the Akt pathway
[35].
RT-PCR can distinguish alterations in CD44 transcription with
much greater sensitivity than ICC [31]. However, RT-PCR must
be interpreted in conjunction with other techniques because
Southern and western blots have revealed that most of the mRNA
transcripts are not translated into protein, implying that over
expression at the protein level might involve only a minority of the
aberrant RNA transcripts [36].
CD44 expression by ICC
ICC revealed that all OPSCC cell lines expressed CD44s,
indicating expression of constitutive exons consistent with matched
PCR data. Only HN12, and OSC-19 gave positive staining for the
products of all variant exons. The remaining cell lines failed to
stain for at least one variant exon. OSC-20 did not stain for the
greatest number of variant exons (v4, v7, v8, and v10). The most
commonly absent variant exon product was v7, followed by v4, v8,
and v10. No relationship could be detected between failure to stain
for a particular variant exon and whether the line was derived
from primary or a metastatic site. For most cell lines translation
did not correlate with transcription as assessed by exon-specific
PCR. This might be due to post translational regulation of
expression, defects in translation mechanisms, but more likely to
be explained by the failure of some antibodies to detect
glycosylated isoforms.
Almost all studies of CD44 expression by HNSCC tissue or cells
lines have used ICC. However, the literature is characterised by
inconsistency. Loss of total CD44 expression has been associated
with metastatic spread, and possibly poor prognosis in HNSCC
[37,38,39], but others have concluded the opposite, that total
CD44 expression is associated with metastasis [40,41,42].
Similar contradictory findings have been published for variant
exon expression. Loss of expression of v2 [43], v3 [44,45], v4/5
[13], v6 [46,47,48,49], v7/8 [15] and v9 [50,51] have been
claimed to correlate with either progression from normal to
dysplasia, or to malignancy, metastasis, or poor survival.
Conversely, down regulation of variant exons v5 and v6 [52],
and v8-10 [14] has been claimed to be unrelated to progression,
metastasis, or poor survival. There is however, general agreement
that expression or over-expression of variant exons v5, v6
[53,54,55,56] and from v4 to v9 [12,57] does not correlate with
tumour progression or predict survival or differ between primary
and metastatic lesions.
These inconsistencies may be due to differences in the grading
systems used for clinical samples, use of different antibodies, and
lack of standard criteria to assess the results. However, there are
more fundamental problems affecting the assessment of CD44
expression by ICC. Provided positive and negative controls are
appropriate, positive staining indicates expression but failure to
stain does not necessarily reflect a lack of expression. The binding
of monoclonal antibodies directed to CD44 exon-specific epitopes
is compromised by the structural variability of the CD44 molecule.
Exon assortment and post-translational modification including
glycosylation, can mask CD44 epitopes. In addition glycosamino-
glycan side chains may disturb more distant epitopes because they
are critical in determining the conformation of a molecule [58]. As
a result, ICC is prone to false negative results and must be
interpreted with caution.
In this study it was found that cells failed to stain most
frequently for variant exon v7 followed by v4, v8, and v10. Few
studies have been carried out with these antibodies on HNSCC
and similar findings have mostly been interpreted as down
regulation or lack of expression. One report concluded failure to
stain for v7 and v9 by OSCC was associated with reduced survival
[11]. Herold-Mende et al also concluded that v7, v8, and v10 were
markedly down regulated in primary HNSCC and were not
detectable in metastatic carcinoma [14]. Lack of v7/8 staining has
also been correlated with poor survival [15].
Staining for v4 has been reported to be lost or reduced in
dysplastic mucosa [57] and loss of v4/5 in .50% of OSCC
metastases [13], 68% of well differentiated tongue SCC’s [45] and
in 70% of poorly and moderately differentiated OSCC [9]. Loss of
staining with v4/5 antibody could indicate down regulation or loss
of either v4, v5, or both. Exon v5 has been generally found to be
expressed by HNSCC [57]. Exons v4 and v5 are transcribed
together and the present results with separate antibodies for v4 and
v5 showing v5 to be present probably indicate that the v4 antibody
is unreliable and that the literature contains mostly false negative
results.
ICC was performed on cells grown for 2 days, because it was
noted that as cells approached confluence, they stained less
intensely and for fewer CD44 isoforms, a phenomenon that
appears to be specific to keratinocytes [59]. This itself is an
interesting finding and suggests that CD44 expression in cell lines
tested remains under relatively normal control, possibly linked to
differentiation or contact inhibition or that there is progressive
synthesis of more heavily glycoslyated forms. The ICC results
presented here are in agreement with the published data, but have
been obtained with a much wider range of antibodies.
CD44 expression analysed by western blotting
Blotting, unlike ICC detects both surface CD44 and smaller
amounts of CD44 in transit in the cytoplasm. The isoforms
detected in positive controls were consistent with the 85–90 kDa N
and O linked glycosylated CD44s form, the 180–200 kDa
chondroitin sulphate linked CD44s form [60,61], the 130–
160 kDa CD44E form [62] and the 230–250 kDa epican or
keratinocyte form known to be present on keratinocytes [63]. All
lines stained with most antibodies except the primary-derived line
HN22, which failed to stain for v3 and the metastatic cell line
OSC-20, which failed to stain for v3 and v6.
There are few published studies with which to compare the
present results. Four studies using WB have been performed on
OSCC. One group used antibody against the constitutive region of
CD44 (Clone E1/E2) and reported that 80% of SCC lines
expressed both CD44s and more abundant forms including
variant exons [9] consistent with the current work. The second
study used antibody only against v3 and claimed to demonstrate a
novel v3-containing isoform (85–90 kDa), in addition to higher
MW bands, in control and hypopharyngeal HNSCC (FaDu) cell
line [64]. In the present work v3 antibody may have stained this
new isoform, as shown by a band at 90 kDa, but bands between
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antibody only against v9 on OSCC lines and detected bands
between 70–190 kDa [50,51]. In the present work, staining with
the same clone of v9 antibody produced two major bands at 120–
130 kDa, probably indicating the epithelial form and a minor
isoform at 180–190 kDa. Bands of MW down to 70 kDa were not
seen. However, the 70 kDa band reported cannot represent v9-
containing isoform because the MW is too low, further evidence of
false positive antibody reactions.
Exon assortment and post translational modification of CD44
variant molecules including glycosylation can mask CD44 exon-
specific epitopes and inhibit detection by antibody [58]. Protein
lysates used in WB are denatured and may generate false negative
results so that negative WB cannot be considered an accurate
indication of lack of expression.
CD44 expression analysed by flow cytometry
FC analysis detects only surface expression of CD44. Most lines
stained with many antibodies with the following exceptions; DT
and OSC-20 were negative for v4 antibody, HN12, OSC-20,
HN30, and HN31 were negative for v10, and most lines were
negative for v7 except HN12, HN8, and OSC-19. FC is also
susceptible to epitope masking though the target cells are in native
configuration. The same antibodies that failed to stain frequently
in ICC also failed to stain in FC. There are no published studies on
HNSCC cell lines that have used FC to analyse CD44 expression
and so the data can only be compared to other antibody
techniques.
Conclusions
From the assessment of multiple transcriptomics data sets in
public databases, we have shown that head and neck cancers
specifically overexpress CD44 compared to other solid cancer
types, suggesting an important role for CD44 in these cancers. In
addition, compared to tissue specimens, cell line models generally
seemed to express lower levels of CD44.
Given the large numbers of CD44 variant transcripts that can be
produced via alternative splicing, we, therefore, investigated
primary and metastatic OPSCC cell lines for potential differences
in variant transcripts and resulting protein. The range of normal
and OPSCC lines tested all transcribed the four common CD44
transcripts v2-10, v3-10, v6-10, and v8-10 except a line termed
HN22, which lacked v3-10. Notably, the splicing patterns were the
same as those in normal epithelium.
CD44 protein splicing patterns were additionally compared to
transcript expression using three independent methods that
resulted in increased sensitivity, reduced the number of negative
results, and gave broad confirmation of the results. Thus, all CD44
exons identified by PCR were confirmed by at least one of the
antibody-based detection methods used. The paired primary and
metastasis-derived cell lines showed minimal differences in CD44
splicing, and there were no major differences that correlated with
the cell line origin or phenotype.
Overall, this study represents the most comprehensive analysis
of CD44 transcription and expression in OPSCC yet performed.
Despite CD44 being highly expressed in comparison to other
cancer types, CD44 variant expression does not seem to be
fundamentally deranged in OPSCC carcinoma lines. Whilst total
CD44 expression is not considered to confer a survival advantage
to head and neck cancers, further investigation is warranted to
determine whether its variant isoforms might offer a survival
advantage or stem cell properties to malignant keratinocytes.
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